Zhang, YuZhu, Hao-YiMa, Cong-CongWang, NingLi, YanLu, Guo-LiangDai, Xing-JieWang, BoMamun, MAALi, YingZhao, Xiao-YingPang, Jing-RuGuo, Ning-JieQi, Feng-YuSun, Jian-GangLiu, Hong-MinLiu, Feng-WuHerdewijn, PietZhao, Long-FeiZheng, Yi-Chao2026-04-122026-04-122026-04Journal of Pharmaceutical Analysis, ISSN: 2095-1779 (Print), Elsevier BV, 101615-101615. doi: 10.1016/j.jpha.2026.1016152095-1779http://hdl.handle.net/10292/20903Highlights • Clusterin (CLU) is a new negative predictive biomarker for anti-PD-1 immunotherapy of gastric cancer (GC). • CLU is a pivotal regulator of both tumor-intrinsic proliferation and immune evasion in GC. • CLU abrogation in GC enhances the immune response, boosting T-cell killing ability activity and cytokine secretion.http://creativecommons.org/licenses/by/4.0/http://creativecommons.org/licenses/by/4.0/32 Biomedical and Clinical Sciences3211 Oncology and Carcinogenesis3204 ImmunologyBiotechnologyRare DiseasesDigestive DiseasesPrecision MedicineCancerStomach CancerImmunizationImmunotherapyVaccine Related5.1 Pharmaceuticals4.1 Discovery and preclinical testing of markers and technologies4.2 Evaluation of markers and technologiesCancerJournal ArticleOpenAccess10.1016/j.jpha.2026.101615